ResMed Inc (RMD)
Gross profit margin
Jun 30, 2024 | Jun 30, 2023 | Jun 30, 2022 | Jun 30, 2021 | Jun 30, 2020 | ||
---|---|---|---|---|---|---|
Gross profit | US$ in thousands | 2,655,300 | 2,355,660 | 2,024,310 | 1,839,100 | 1,717,790 |
Revenue | US$ in thousands | 4,681,150 | 4,175,350 | 3,649,870 | 3,265,510 | 2,957,010 |
Gross profit margin | 56.72% | 56.42% | 55.46% | 56.32% | 58.09% |
June 30, 2024 calculation
Gross profit margin = Gross profit ÷ Revenue
= $2,655,300K ÷ $4,681,150K
= 56.72%
ResMed Inc's gross profit margin has shown stability over the past five years, ranging from 55.46% in June 2022 to 58.09% in June 2020. The company's ability to generate profit from its core operations has been consistent, with the most recent figure reported at 56.72% in June 2024. This indicates that ResMed Inc effectively manages its production costs and pricing strategies to maintain a healthy level of profitability. While there have been minor fluctuations, the overall trend suggests a solid performance in terms of gross profit margin.
Peer comparison
Jun 30, 2024
Company name
Symbol
Gross profit margin
ResMed Inc
RMD
56.72%
3M Company
MMM
43.46%
Artivion Inc
AORT
69.22%
Baxter International Inc
BAX
33.51%
Becton Dickinson and Company
BDX
5.65%
Boston Scientific Corp
BSX
70.81%
DexCom Inc
DXCM
63.52%
Embecta Corp
EMBC
67.44%
Glaukos Corp
GKOS
79.40%
Globus Medical
GMED
65.05%
Haemonetics Corporation
HAE
26.65%